Search results for "platelet aggregation inhibitors"

showing 10 items of 105 documents

Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers

2011

AdultMalePlatelet aggregationPlatelet AggregationFlowerslaw.inventionYoung AdultRandomized controlled trialFibrinolytic AgentslawHealthy volunteersMedicineHumansAnalysis of VarianceCrataegusCross-Over StudiesbiologyTraditional medicineAspirinbusiness.industryPlant ExtractsHematologybiology.organism_classificationCrossover studyCrataegus laevigataPlant LeavesThromboxane B2SpainFemaleAnalysis of variancebusinessPlatelet Aggregation Inhibitors
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Dental extractions in patients on antiplatelet therapy. A study conducted by the Oral Health Department of the Navarre Health Service (Spain).

2008

Objectives: Antiplatelet drugs are used to treat and prevent a wide range of cardiovascular pathologies and/or cerebrovascular accidents. Although the use of anticoagulants in dental extractions is highly protocolized, a clear control method has not yet been established for antiplatelet drugs. This study is directed at evaluating the clinical consequences of extractions in patients on antiplatelet therapy. Study design: The Oral Health Department of the Navarre Health Service-Osasunbidea conducted a trial on 155 patients who underwent dental extractions and were receiving antiplatelet therapy. The patients were not requested to interrupt the medication and local measures were taken to contr…

AdultMalemedicine.medical_specialtyMEDLINEDentistryOral healthPostoperative HemorrhageHealth servicesRisk FactorsMedicineHumansIn patientGeneral DentistryAgedAged 80 and overbusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologySpainEmergency medicineUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemalebusinessControl methodsPlatelet Aggregation InhibitorsMedicina oral, patologia oral y cirugia bucal
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct

Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

2004

Abstract Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM). In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900mg) of triflusal, and aspirin (100mg/day) on urinary 11-dehydro-thromboxane (TX)B 2 , index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite a…

AdultMalemedicine.medical_specialtyThromboxaneaspirinRadioimmunoassaychemistry.chemical_compoundThromboxane A2Von Willebrand factorDouble-Blind MethodInternal medicinetype 2 diabetes triellitusvon Willebrand Factormedicineplatelet activationHumansPlateletPlatelet activationAgedRetrospective StudiesAspirinbiologyDose-Response Relationship DrugMiddle AgedSalicylatesThromboxane B2Thromboxane B2triflusalP-SelectinEndocrinologychemistryDiabetes Mellitus Type 2biology.proteinTriflusalFemaleCardiology and Cardiovascular MedicineBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFollow-Up Studies
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial. The CLOSE-MIG study.

2021

International audience; Background and purpose The efficacy of patent foramen ovale (PFO) closure to reduce the frequency of migraine attacks remains controversial. Methods This was a planned sub-study in migraine patients enrolled in a randomized, clinical trial designed to assess the superiority of PFO closure plus antiplatelet therapy over antiplatelet therapy alone to prevent stroke recurrence in patients younger than 60 years with a PFO-associated cryptogenic ischaemic stroke. The main outcome was the mean annual number of migraine attacks in migraine patients with aura and in those without aura, as recorded at each follow-up visit by study neurologists. Results Of 473 patients randomi…

Adultmedicine.medical_specialtyStroke patientAuraSeptal Occluder Device[SDV]Life Sciences [q-bio]Migraine DisordersForamen Ovale PatentBrain Ischemia03 medical and health sciences0302 clinical medicineInternal medicineIschaemic strokemedicineHumans030212 general & internal medicineClosure (psychology)Foramen ovale (heart)business.industryMiddle Agedmedicine.diseaseClinical trialStrokemedicine.anatomical_structureTreatment OutcomeNeurologyMigraineCardiologyPatent foramen ovaleFemaleNeurology (clinical)business030217 neurology & neurosurgeryPlatelet Aggregation InhibitorsEuropean journal of neurologyREFERENCES
researchProduct

Prostacyclin receptor desensitization is a reversible phenomenon in human platelets.

1997

Background Long-term exposure of platelets to endogenous or exogenous prostacyclin or its analogues might result in desensitization of the platelet prostacyclin receptor in vitro and in vivo accompanied by a loss in receptor density on the platelet surface and a reduced sensitivity toward the inhibitory effects of prostacyclins. However, the reversibility of this process in platelets has not yet been investigated. Methods and Results Human platelets desensitized by the chemically stable prostacyclin analogue iloprost showed a significant reduction in [ 3 H]-iloprost binding sites that was reversed by saponin permeabilization. This indicates functionally active internalized prostacyclin rec…

AgonistBlood PlateletsMalemedicine.medical_specialtyCell Membrane Permeabilitymedicine.drug_classReceptors ProstaglandinProstaglandinProstacyclinReceptors EpoprostenolProstacyclin receptor bindingchemistry.chemical_compoundReference ValuesPhysiology (medical)Internal medicinemedicineCyclic AMPHumansPlateletIloprostProstacyclin receptorbusiness.industryEndocrinologychemistrycardiovascular systemPlatelet aggregation inhibitorlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugIloprostCirculation
researchProduct

Initiation and duration of dual antiplatelet therapy after inpatient percutaneous coronary intervention with stent implantation in Germany: An electr…

2017

Abstract Background Studies assessing the routine outpatient dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in Germany are scarce. The aim of this study was (i) to investigate the initiation and duration of DAPT after inpatient PCI with stent implantation in Germany, and (ii) to identify factors associated with DAPT discontinuation during the recommended treatment period. Methods This retrospective cohort study was based on data from a large German electronic healthcare database of the years 2004 to 2009. The study population comprised four groups of patients with acute coronary syndrome (ACS) or stable angina pectoris undergoing inpatient PCI with either ba…

Bare-metal stentmedicine.medical_specialtyAcute coronary syndromeTime Factorsanimal structuresmedicine.medical_treatmentMedicine (miscellaneous)030204 cardiovascular system & hematologyEducation03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineGermanymedicineHumanscardiovascular diseases030212 general & internal medicineRetrospective StudiesInpatientsbusiness.industryHealth PolicyPercutaneous coronary interventionStentDrug-Eluting StentsRetrospective cohort studymedicine.diseaseSurgeryDiscontinuationTreatment OutcomeDrug-eluting stentConventional PCIStentsbusinessPlatelet Aggregation InhibitorsZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
researchProduct

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

2006

Platelet activation causes conformational changes of integrin GPIIb/IIIa (α IIb β 3 ), resulting in the exposure of its ligand-binding pocket. This provides the unique possibility to design agents that specifically block activated platelets only. We used phage display of single-chain antibody (scFv) libraries in combination with several rounds of depletion/selection to obtain human scFvs that bind specifically to the activated conformation of GPIIb/IIIa. Functional evaluation of these scFv clones revealed that fibrinogen binding to human platelets and platelet aggregation can be effectively inhibited by activation-specific scFvs. In contrast to clinically used GPIIb/IIIa blockers, which ar…

Blood PlateletsCarotid Artery DiseasesBleeding TimePhysiologyAmino Acid MotifsMolecular ConformationEptifibatidePlatelet Glycoprotein GPIIb-IIIa ComplexFerric CompoundsAntibodiesMiceChloridesFibrinolytic AgentsmedicineAbciximabAnimalsHumansPlateletPlatelet activationChemistryFibrinogen bindingFibrinogenThrombosisTirofibanPlatelet ActivationMolecular biologyComplementarity Determining RegionsMice Inbred C57BLTirofibanImmunologyEptifibatidePlatelet aggregation inhibitorTyrosineCardiology and Cardiovascular MedicineGlycoprotein IIb/IIIaPeptidesPlatelet Aggregation Inhibitorsmedicine.drugCirculation research
researchProduct